×

Biotech and Pharmaceuticals Life Sciences

  • *Analysts say failure puts approval at risk. ZURICH, May 10- Roche's Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine. Roche, the world's biggest maker of cancer drugs, had won...

  • *AstraZeneca sets durvalumab price at $15,000/ month. Leerink analyst Seamus Fernandez sees durvalumab capturing a modest 10 percent of the estimated $2.3 billion global bladder cancer market, while AstraZeneca in 2014 put the drug's peak sales in all cancers at $6.5 billion, including combination use. The U.S. Food and Drug Administration said late on Monday...

  • *AstraZeneca sets durvalumab price at $15,000/ month. May 1- U.S. regulators have approved AstraZeneca's key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars. The U.S. Food and Drug Administration said on Monday it granted accelerated...

  • LONDON, April 27- AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Despite income from disposals and external deals, first-quarter revenue fell 12 percent to $5.4 billion, although core...

  • LONDON, April 27- AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Despite income from disposals and external deals, first-quarter revenue fell 12 percent to $5.4 billion, although core...

  • LONDON, April 27- AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Despite income from disposals and external deals, first-quarter revenue fell 12 percent to $5.4 billion, although core...

  • *Agreed Akorn bid of $34 per share. FRANKFURT, April 25- German healthcare group Fresenius SE& Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars arm of Germany's Merck KGaA. But his successor, former finance chief Stephan Sturm, is lifting the pace, having already bought a Spanish hospital...

  • *Agreed Akorn bid of $34 per share. FRANKFURT, April 24- German healthcare conglomerate Fresenius SE& Co KGaA revved up the pace of its deals by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion, and in a separate agreement, the biosimilars unit of German peer Merck KGaA. A lot has been done in that area in the recent past, "Fresenius Chief Executive Stephan...

  • LONDON, April 20- The biotech company behind the Western world's first gene therapy and the most expensive prescription medicine in history is giving up on the product because of lack of demand. Only one patient has been treated commercially since the drug was first approved in Europe nearly five years ago, a spokeswoman for Dutch-based UniQure said on...

  • LONDON, April 18- Britain's Circassia Pharmaceuticals is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader respiratory business. The top shareholders in Circassia, which listed on the London stock market in March 2014 in Britain's largest biotech flotation for decades, are...

  • WASHINGTON, April 14- The U.S. Food and Drug Administration on Friday declined to approve a new drug for rheumatoid arthritis made by Eli Lilly and Co and partner Incyte Corp, the companies said on Friday. FDA indicated that additional clinical data was needed to determine the most appropriate doses of the drug, Olumiant, known also as baricitinib, and to further...

  • CNBC reporter Christina Farr discusses her exclusive scoop that Apple is moving into life science with a team working on glucose-sensing technology.

  • April 3- Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year. The industry's pipeline of cancer drugs expanded by 63 percent between 2005 and 2015, according to the QuintilesIMS Institute, and a good number are reaching the market.

  • March 28- The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the biotech drug known...

  • March 27- The U.S. Food and Drug Administration on Monday approved Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer. The U.S. biopharmaceutical company's shares were up 7.78 percent at $168.9 in extended trading. Tesaro expects to launch niraparib in the United States in late April.

  • The Food and Drug Administration said it approved Bavencio, known chemically as avelumab, to treat metastatic Merkel cell carcinoma in patients 12 years and older. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in a statement. About 1,600 people in the United States are diagnosed with MCC every year, according to the National Cancer...

  • Stephen Hawking in London in 2015.

    British physicist Stephen Hawking fears he won't be welcome in the U.S. due to his criticism of how President Trump is treating scientists.

  • Hello, what a better night's sleep?

    James Proud, Hello founder & CEO talks about a tech device that monitors and improves sleep.

  • *British company licenses two COPD drugs from AstraZeneca. LONDON, March 17- Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease, a progressive lung condition affecting millions of people, for up to $230 million. Circassia's Chief Executive Steve Harris said Tudorza, a bronchodilator...

  • "The persistence of vaccine-induced immunity to one year post-immunisation is truly impressive," said researcher Matthew Snape of the University of Oxford. That is different from another Ebola vaccine from Merck, which was the first to prove effective in preventing human infection during a large trial in Guinea last year. Scientists have been racing to...